Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 24.44

-1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nancy who wrote (1048)	11/14/1998 9:52:00 AM
From: Henry Niman	Read Replies (1) of 1722

The BBRS conference call mentioned the lack of Medicare coverage, which they said represented about 1/3 of the patients and it was not covered because injections are at home and not in doctor's office, in contrast to Remicade infusions. BBRS cited an annual treatment cost for Enbrel in the $10-11,000 range, with Remicade itself costing about $6500 per year (excluding infusion costs which level the playing field as far as total treatment costs are concerned, but offer Drs an additional revenue source since they infuse the Remicade, and have an additional service to charge for). More details in the TNF Inhibitor table on the New Therapeutics page at biocognizance.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next